German therapeutic company ProBioGen has entered a licence and cooperation agreement to grant use of its human lymph node technology in TissUse's multi-organ-chip applications.
ProBioGen’s Human Artificial Lymph Node (HuALN) model will be integrated into the TissUse Multi-Organ-Chip technology.
Go deeper with GlobalData
HuALN was designed as a 3D micro-organoid model for in-vitro analysis of substance effects on the human immune system.
The model is based on a miniaturised and perfused bioreactor, which is inoculated with human blood-derived dendritic cells and T and B lymphocytes. It is also injected with mesenchymal stem cell-derived stromal cells in a 3D hydrogel matrix, which contains cell culture medium and aeration to resemble a human lymph node.
The Lymph Node Model monitors direct effects of substances on the human immune system, while the Multi-Organ-Chip technology mimics various interacting human organs on a device to simulate the human processes over a period of approximately two months.
HuALN analyses the immunofunctions, including immunomodulation, immunogenicity, and immunotoxicity.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataTissUse CEO Dr Uwe Marx said: “The combination of ProBioGen’s unique HuALN model and our human Multi-Organ-Chip technology will in future initially allow for the analysis of immunological reactions of human organs on active substances.
“Disease mechanisms in systemic autoimmunological diseases, allergies and anti-tumoural reactions will be elucidated with such Multi-Organ-Chip systems.”
The technology is expected to enable investigation of the body’s reaction to new biopharmaceuticals, vaccines, cosmetics or chemicals without the use of animal testing.
It provides read-outs on the T and B cell level, specifically on cytokine profiles, cell surface markers, cell proliferation, IgM and IgG secretion, anti-drug antibodies, and functional cell tests.
